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Is interim 18F-fluoride PET/CT a predictor of outcomes after 
radium-223 therapy?
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Abstract
Resumo
Objective: To determine whether an interim 18F-fluoride positron-emission tomography/computed tomography (PET/CT) study per-
formed after the third cycle of radium-223 dichloride (223RaCl2) therapy is able to identify patients that will not respond to treatment.
Materials and Methods: We retrospectively reviewed 34 histologically confirmed cases of hormone-refractory prostate cancer with 
bone metastasis in patients submitted to 223RaCl2 therapy. All of the patients underwent baseline and interim 18F-fluoride PET/CT 
studies. The interim study was performed immediately prior to the fourth cycle of 223RaCl2. The skeletal tumor burden—expressed as 
the total lesion fluoride uptake above a maximum standardized uptake value of 10 (TLF10)—was calculated for the baseline and the in-
terim studies. The percent change in TLF10 between the baseline and interim studies (%TFL10) was calculated as follows: %TFL10 = in-
terim TLF10 − baseline TLF10 / baseline TLF10. End points were overall survival, progression-free survival, and skeletal-related events.
Results: The mean age of the patients was 72.4 ± 10.2 years (range, 43.3–88.8 years). The %TLF10 was not able to predict overall 
survival (p = 0.6320; hazard ratio [HR] = 0.753; 95% confidence interval [CI]: 0.236–2.401), progression-free survival (p = 0.5908; 
HR = 1.248; 95% CI: 0.557–2.797) nor time to a bone event (p = 0.5114; HR = 1.588; 95% CI: 0.399–6.312).
Conclusion: The skeletal tumor burden on an interim 18F-fluoride PET/CT, performed after three cycles of 223RaCl2, is not able to pre-
dict overall survival, progression-free survival, or time to bone event, and should not be performed to monitor response at this time.
Keywords: Sodium fluoride; Positron-emission tomography/methods; Tomography, X-ray computed/methods; Prostatic neoplasms; 
Radium-223; Bone neoplasms/diagnostic imaging; Tumor burden.
Objetivo: Avaliar se o PET/CT interim com fluoreto-18F após a terceira dose da terapia com dicloreto de rádio-223 (223Ra) é capaz 
de identificar pacientes que não responderão ao tratamento.
Materiais e Métodos: Revisamos, retrospectivamente, 34 pacientes com diagnóstico histológico de câncer de próstata refratários 
a hormonioterapia e com metástases ósseas que foram submetidos a 223Ra. Todos os pacientes foram submetidos a PET/CT 
com fluoreto-18F antes de iniciar o tratamento (basal) e imediatamente antes da quarta dose de 223Ra (interim). A carga tumoral 
esquelética (TLF10) foi calculada em ambos os exames da PET/CT com fluoreto-18F de cada paciente e foi determinada a alteração 
percentual na TLF10 entre eles (%TFL10 = TLF10 interim – TLF10 basal / TLF10 basal). Foram avaliados a sobrevida global, a sobrevida 
livre de progressão e o tempo para um evento ósseo.
Resultados: A idade média dos pacientes foi 72,4 ± 10,2 anos (variação: 43,3–88,8 anos). A %TLF10 não foi capaz de predizer 
a sobrevida global (p = 0,6320; HR = 0,753; intervalo de confiança [IC] 95%: 0,236–2,101), a sobrevida livre de progressão (p = 
0,5908; HR = 1,248; IC 95%: 0,557–2,797) nem o tempo para um evento ósseo (p = 0,5114; HR = 1,588; IC 95%: 0,399–6,312).
Conclusão: A carga tumoral esquelética da PET/CT com fluoreto-18F realizada após três doses de 223Ra não é capaz de predizer 
sobrevida global, sobrevida livre de progressão ou tempo até um evento ósseo, e não deve ser realizada para monitorar a resposta 
ao tratamento desses pacientes, nesse momento.
Unitermos: Fluoreto de sódio; Tomografia por emissão de pósitrons/métodos; Tomografia computadorizada/métodos; Neoplasias 
da próstata; Rádio-223; Neoplasias ósseas/diagnóstico por imagem; Carga tumoral.
therapy(1). However, although treatment with 223RaCl2 
improves survival in prostate cancer patients(2–4), not all 
patients respond to this therapy. It would be beneficial to 
identify nonresponders early in the course of treatment, 
thereby reducing morbidity and unnecessary costs.
INTRODUCTION
Baseline whole-body 18F-fluoride PET/CT is ideal for 
staging and restaging prostate cancer and has been shown 
to be an independent prognostic imaging biomarker of 
patients undergoing radium-223 dichloride (223RaCl2) 
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After successful treatment of osteoblastic bone metas-
tases, an osteoblastic reaction (flare) can occur, which in-
creases bone uptake even in responsive cases. That can be 
confused with the osteoblastic reaction and inflammation 
that occur in response to tumor-associated growth factors 
during progression. This phenomenon has been well de-
scribed in conventional bone scintigraphy, and that method 
is therefore not recommended for use as the sole means of 
determining the response to treatment(5,6).
Although interim studies performed with 18F-FDG 
PET/CT can change the management of patients with a 
variety of cancer types(7–10), the exact role of 18F-fluoride 
PET/CT in evaluating the early response to therapy (interim 
study) is not well established. The importance of 18F-fluo-
ride PET/CT has extended beyond the diagnosis of metas-
tases to the evaluation of optimal strategies for use in pa-
tients submitted to treatment with new therapeutic agents. 
Chemotherapy, hormone therapy, immunotherapy, and 
radionuclide therapies such as those involving 223RaCl2
(11) 
are costly approaches. Therefore, the ability to predict re-
sponse, thereby avoiding overtreatment and reducing costs, 
will improve patient management. The purpose of this 
study was to determine whether an interim 18F-fluoride 
PET/CT study is able to evaluate treatment responses in 
prostate cancer patients submitted to 223RaCl2 therapy.
MATERIALS AND METHODS
The local institutional review board approved this 
retrospective analysis (reference no. PA14-0848). We ret-
rospectively reviewed histologically confirmed cases of 
hormone-refractory prostate cancer with bone metasta-
sis in patients receiving 223RaCl2 therapy and undergoing 
two 18F-fluoride PET/CT studies—a baseline study and 
an interim study (immediately prior to the fourth cycle of 
223RaCl2)—at our facility. All patients completed at least 
four cycles of 223RaCl2 (Xofigo; Bayer Pharma AG, Berlin, 
Germany), receiving intravenous infusions of 50 kBq/kg 
(1.4 µCi/kg) of 223RaCl2 at monthly intervals.
18F-fluoride PET/CT acquisition
18F-fluoride PET/CT images were acquired immedi-
ately prior to initiation of the 223RaCl2 therapy (baseline 
study) and immediately before the fourth cycle (interim 
study). True whole-body PET images were obtained 50–60 
min after intravenous injection of 158–370 MBq of 18F-
sodium fluoride in dedicated PET/CT scanners (Discov-
ery STe, RX, or VCT; 16 or 64 channel; GE Healthcare, 
Milwaukee, WI, USA, or Siemens mCT Flow; 64 channel; 
Siemens Healthcare, Knoxville, TN, USA), and whole-body 
noncontrast CT scans were used for attenuation correction.
18F-fluoride PET/CT interpretation and quantification
Two board-certified nuclear medicine physicians eval-
uated baseline and interim 18F-fluoride PET/CT images. 
Visual and quantitative analyses were performed.
Visual analysis
In the visual analysis, we compared the baseline and 
interim studies, classifying the responses as follows:
• Complete response – Osteoblastic bone metastases 
identified in the baseline study no longer being present in 
the interim study.
• Partial response – Interim study showing decreased 
uptake in pre-existing bone metastases.
• Stable disease – No difference between the interim 
and baseline scans in terms of the uptake in pre-existing 
bone metastases.
• Progressive disease – Interim study showing an in-
crease in the uptake or volume of a pre-existing bone me-
tastases or new osteoblastic metastases.
The patients were followed for confirmation of these 
response classifications. The follow-up reference standards 
used in order to determine if the response classification was 
correct (i.e., to identify true-positive, true-negative, false-
positive, and false-negative responses) included clinical pa-
rameters—such as clinical worsening, disease progression, 
bone events, and death; biochemical parameters—such as 
the levels of alkaline phosphatase (ALP) and prostate-spe-
cific antigen (PSA); and imaging findings—such as those 
obtained with 18F-fluoride PET/CT, 18F-FDG PET/CT, 
bone scans, or CT scans. On the interim 18F-fluoride PET/
CT study, images that demonstrated stable disease, a partial 
response, or a complete response were all considered to rep-
resent a true-positive response to therapy if the reference 
standards also indicated that the patient had responded to 
therapy (no clinical worsening, progression, or increase in 
the levels of the biochemical markers) or a false-positive 
response to therapy if those same standards demonstrated 
progressive disease (new areas of disease, clinical worsen-
ing, or death). In contrast, images that demonstrated pro-
gressive disease were considered to represent a true-nega-
tive response to therapy if the reference standards also indi-
cated that the patient had not responded to therapy and it 
was confirmed during follow-up that there was no response 
to therapy or a false-negative response to therapy (flare re-
sponse) if those same standards demonstrated a response 
(no clinical worsening, progression, or increase in the levels 
of the biochemical markers).
Quantitative analysis
Using quantitative analysis, we determined the whole-
body skeletal tumor burden in the baseline and interim 18F-
fluoride PET/CT images. The skeletal tumor burden was 
determined after establishing the maximum standardized 
uptake value (SUVmax) threshold ≥ 10 to exclude normal 
bone(12). To that end, we initially obtained the volume (in 
milliliters) of total fluoride activity, defined as the fluoride 
tumor volume above an SUVmax of 10 (FTV10), within the 
volume of interest (VOI). The FTV10 calculation is equiva-
lent to the metabolic tumor volume calculation used in 18F-
FDG PET/CT studies. The total fluoride lesion uptake above 
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an SUVmax of 10 (TLF10) was then calculated as the product 
of mean SUVmax × FTV10. The TLF10 is equivalent to the 
total lesion glycolysis used in 18F-FDG PET/CT studies. To 
evaluate the performance of interim 18F-fluoride PET/CT, 
the percent change in the skeletal tumor burden between 
the baseline and interim studies was calculated as follows: 
%TLF10 = interim TLF10 − baseline TLF10 / baseline TFL10
Statistical analyses
Categorical variables were expressed as absolute and 
relative frequencies, whereas continuous variables were 
expressed as mean ± standard deviation when presenting 
normal distribution and as median (minimum-maximum) 
when presenting non-normal distribution. All outcome 
measures were correlated with the %TFL10 values ob-
tained. The primary end point was overall survival (OS), 
which was calculated from the first 223RaCl2 cycle to the 
date of death or last follow-up. Secondary end points 
were progression-free survival (PFS), time to a bone event 
(TTBE), and bone marrow failure (BMF). PFS was calcu-
lated from the first 223RaCl2 cycle to the date of progres-
sion, death, or last follow-up. The TTBE was calculated 
as the time from the date of the first 223RaCl2 cycle to the 
next bone event. Lastly, BMF was defined as the develop-
ment of hematologic toxicity (World Health Organization 
grade 3 or 4), together with no recovery after six weeks or 
death due to BMF after the last 223RaCl2 cycle.
Kaplan-Meier survival curves were generated, and Cox 
proportional hazards regression was used in order to ana-
lyze predictors of survival. Backward stepwise selection was 
performed for multivariate Cox models. Logistic regression 
was used in order to model the odds of a bone event as a 
function of all of the PET variables. We used Spearman’s 
correlation coefficient to assess the level of agreement be-
tween the PET variables. For the statistical analyses, we 
used the Statistical Analysis System, version 9.3 for Win-
dows (SAS Institute Inc., Cary, NC, USA).
RESULTS
We analyzed the cases of 34 patients, with a mean age 
of 72.4 ± 10.2 years (median, 72.5 years; range, 43.3–88.8 
years) (Table 1), who had had prostate cancer for a mean 
of 6 ± 4 years (range, 2–20 years). The mean Gleason 
score was 7 ± 3. Prior to the initiation of 223RaCl2 therapy, 
26.9% of the patients had received chemotherapy, 5% had 
received radiotherapy, 59% had received hormone therapy, 
and 9% had received blood transfusion. At the first 223RaCl2 
cycle, the mean ALP was 193.9 IU/L and the mean PSA 
was 103.2 ng/mL. The median time of follow-up after the 
interim study was 28.1 months (range, 11–52 months). 
The 34 patients were submitted to a collective total of 179 
223RaCl2 cycles: 55.9% of the patients received six cycles of 
223RaCl2; 14.7% received five cycles; and 29.4% received 
four cycles. The principal causes of treatment interrup-
tion were progression (in 44.4%), hematologic toxicity (in 
17.8%), a significant decline of the Eastern Cooperative 
Oncology Group performance status (in 13.3%), and a 
bone event (in 2.2%).
Visual analysis of interim 18F-fluoride PET/CT
A complete response was not perceived in any of the 
interim 18F-fluoride PET/CT studies or on the basis of the 
follow-up reference standards. A partial response was iden-
tified in 16 (47%) of the patients in the interim 18F-fluoride 
PET/CT studies (Figure 1), and the reference standards 
demonstrated that a partial response had indeed been 























Figure 1. A patient with hormone-refractory prostate cancer, accompanied by 
bone metastasis, who showed a partial response to 223RaCl2, and the interim 
18F-fluoride PET/CT study demonstrating a true-positive response. A: The base-
line 18F-fluoride PET/CT study revealing widespread osteoblastic metastases. 
B: The interim 18F-fluoride PET/CT study, performed after the third 223RaCl2 cy-
cle, showing a reduction in osteoblastic metastases, especially in the rib cage, 
pelvis, and right femur, consistent with a partial response to 223RaCl2. There 
was a 70% reduction in the %TLF10. During follow-up, the ALP levels dropped 
and no new bone lesions appeared. After the last 223RaCl2 cycle, the patient 
resumed enzalutamide to control lymph node metastases that had been pres-
ent prior to the first 223RaCl2 cycle.
A B
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achieved in eight of those patients (true-positive cases), 
whereas the other eight patients had progressed (false-pos-
itive cases), as shown in Figure 2. Stable disease was noted 
in five (15%) of the patients in the interim 18F-fluoride 
PET/CT studies, although only three of those patients were 
categorized as true-positive cases (showing stable disease 
or a partial response), whereas the two remaining patients 
progressed. Progressive disease was identified in 13 (38%) 
of the patients in the interim 18F-fluoride PET/CT stud-
ies, 12 (35.3%) of whom were categorized as true-nega-
tive cases (Figure 3), the remaining patient (3.0%) being 
categorized as a false-negative case because the increased 
uptake noted on the interim 18F-fluoride PET/CT (when 
compared with that observed in the baseline study) was 
actually due to a flare phenomenon (Figure 4). Therefore, 
the responses were categorized as true positive in 11 cases 
(32.4%), false positive in 10 (29.4%), true negative in 12 
(35.3%), and false negative in 1 (2.9%). 
The interim 18F-fluoride PET/CT study was found to 
have a sensitivity of 91.6%, a specificity of 54.5%, a posi-
tive predictive value of 52.4%, a negative predictive value of 
92.3%, and an accuracy of 67.6% (Figure 5). For distinguish-
ing between responders and nonresponders, a reduction in 
the ALP level had a sensitivity of 38% and a specificity of 85% 
when the follow-up parameters were taken as the reference.
Quantitative analysis of interim 18F-fluoride PET/CT
Figure 6 illustrates the quantitative method employed 
to obtain the TLF10 and FTV10 values. Spearman’s correla-
tion coefficient showed that the %TLF10 and %FTV10 values 
correlated strongly with each other (rho = 0.95). Therefore, 
Figure 3. A patient with hormone-refractory prostate cancer, accompanied 
by bone metastasis, who showed progression during 223RaCl2 therapy. A: 
The baseline 18F-fluoride PET/CT study showing widespread osteoblastic 
metastases. B: The interim 18F-fluoride PET/CT study, performed after the 
third 223RaCl2 cycle, showing increased uptake in the known osteoblastic 
metastases and new lesions, especially in the pelvis, consistent with pro-
gression. The %TLF10 increased by 104%; PSA and ALP levels continued to 
rise; new bone metastases developed; a liver metastasis developed; and 
there was further enlargement of previously enlarged lymph nodes. The pa-
tient started a new chemotherapy regimen but died eight months after the 
last 223RaCl2 cycle.
A B
Figure 2. A patient with hormone-
refractory prostate cancer, ac-
companied by bone metastasis, 
who showed progression during 
223RaCl2 therapy but was catego-
rized as a false-positive case on 
the basis of the imaging findings. 
A: The baseline 18F-fluoride PET/
CT study showing osteoblastic 
metastases. B: The interim 18F-
fluoride PET/CT study, performed 
after the third 223RaCl2 cycle, 
showing a slight reduction in up-
take by the known osteoblastic 
metastases and no new lesions, 
consistent with a partial response. 
Although the %TLF10 decreased 
by 44%, the PSA and ALP levels 
continued to rise and there was 
rapid progression of the bone me-
tastases. Therefore, the patient 
was started on cyclophosphamide 
and subsequently on dasatinib. 
C: A follow-up 18F-fluoride PET/
CT study, conducted after the 
sixth 223RaCl2 cycle, showed wide-
spread osteoblastic metastases.A B C
Etchebehere E et al. / Interim 18F-fluoride PET/CT during radium therapy
37Radiol Bras. 2019 Jan/Fev;52(1):33–40
A B
Figure 4. A patient with hormone-refractory prostate cancer, accompanied by 
bone metastasis, who responded to 223RaCl2 but was categorized as a false-
negative case on the basis of the imaging findings. A: The baseline 18F-fluoride 
PET/CT study showing osteoblastic metastases. B: The interim 18F-fluoride 
PET/CT study, performed after the third 223RaCl2 cycle, showing increased up-
take in the known osteoblastic metastases but no new lesions. Although that 
pattern is consistent with progression (with a %TLF10 increase of 65%), the 
PSA and ALP dropped remarkably, after which the patient responded and was 
stable at 12 months after the last 223RaCl2 cycle. Therefore, the images were 
clearly due to a flare (false-negative) response.
Figure 6. Example of determination of TLF10 and FTV10. A: A semi-automatic VOI (orange rectangle) is placed within the whole-body maximum intensity projection 
image. A threshold SUVmax of 10 is then established as the cut-off to separate normal bone from abnormal bone. Consequently, the software will automatically 
delineate only SUVmax regions above the set threshold of 10, defining the VOI with an isocontour threshold set at 41% of the SUVmax. After all regions have been 
defined, a careful inspection should be performed to exclude all non-tumor-related VOIs. The sum of all the VOIs outlined with the SUVmax of 10 provides the FTV10. 
To obtain the TLF10, the FTV10 is multiplied by the SUVmean10 (VOI10 × mean10), which is also measured in milliliters. B: In this particular example, the patient had 
only one lesion with an SUVmax higher than 10, which corresponded to a rib metastasis with an SUVmax of 25. The TLF10 was 65.8, and the FTV10 was 4.2.
A B
only the %TLF10 values were applied to subsequent analy-
ses. The median TLF10 was 7374 (range, 391–46,550) in 
the baseline 18F-fluoride PET/CT study and 5632 (range, 
486–30,200) in the interim study. 
At the end of the follow-up period, 32 (94%) of the 
patients had progressed and 17 (53%) had died (Table 2). 
The average time to progression was 4.7 ± 2.9 months (me-
dian, 3.1 months; range, 0.9–12.1 months), and the most 
common type of progression was metastasis to the bone 
Figure 5. Visual analysis and evolution of the 34 patients.
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(in 39.1%), followed by nodal metastases (in 25.0%) and 
visceral metastases (in 21.9%).
In our study sample, the %TLF10 on the interim 
18F-
fluoride PET/CT was not able to predict OS (p = 0.6320; 
HR = 0.753; 95% CI: 0.236–2.401) or PFS (p = 0.5908; 
HR = 1.248; 95% CI: 0.557–2.797). Six patients had a 
bone event, and %TLF10 was also unable to predict the 
TTBE (p = 0.5114; HR = 1.588; 95% CI: 0.399–6.312). 
Nine patients developed BMF after 223RaCl2, and %TLF10 
was also not a significant univariate predictor of the odds 
of developing that condition (p = 0.6071; HR = 1.401; 95% 
CI: 0.387–5.070). We found that OS did not correlate with 
the SUVmax (p = 0.7989), any nodal disease (p = 0.1342), 
or visceral disease (p = 0.1496).
DISCUSSION
We have demonstrated that an interim 18F-fluoride 
PET/CT study is unable to predict outcomes after 223RaCl2 
therapy. Novel therapies for osteoblastic metastases, in-
cluding 223RaCl2 therapy, are costly, and it is therefore im-
portant to establish a diagnostic test to predict responses 
to these new, expensive treatments. In one study evaluat-
ing treatment responses after six cycles of 223RaCl2 in ten 
patients(13), conventional bone scintigraphy demonstrated 
that increased areas of uptake were due not only to treat-
ment response but also to reparative bone changes after 
therapy (a flare response).
Previous studies have shown that a baseline 18F-flu-
oride PET/CT study plays a prognostic role in patients 
with breast or prostate cancer treated with 223RaCl2
(1,14). 
However, 18F-fluoride PET/CT is not traditionally used in 
evaluating the response to any therapy, because the pro-
cess of bone healing involves an osteoblastic reaction than 
can increase 18F-fluoride uptake, as in conventional bone 
scintigraphy(15). Because of comparable pharmacokinetics 
between 223RaCl2
(2) and 18F-fluoride(16), we hypothesized 
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that 18F-fluoride would be able to evaluate osteoblastic me-
tastases before, during, and after 223RaCl2 therapy.
In our study sample, the interim study demonstrated 
that a decrease in uptake was generally due to a response 
(partial or stable disease) to therapy. However, we find it in-
teresting that, in six (17.6%) of the patients, the decreased 
uptake was caused by extensive tumor infiltration of the 
bone marrow, ultimately leading to BMF. To our knowledge, 
there have been no previous studies describing the latter im-
aging pattern (caused by BMF) in interim studies. In con-
trast, although the interim study was able to demonstrate 
that increased uptake was due to progression, that pattern 
of uptake was in fact a flare phenomenon in one case. This 
increased uptake most likely occurred because of the bone 
healing process after successful 223RaCl2 treatment, which 
involves an osteoblastic reaction. In the subset of patients 
in which the flare phenomenon occurred, the CT portion 
of the study revealed reparative changes with increased ex-
tent of the sclerotic lesions. However, even on CT, it was 
not possible to determine which patients were progressing 
and which were responding. Although we hypothesized that 
bone levels of ALP could help evaluate patient outcomes, it 
demonstrated higher specificity and lower sensitivity than 
did the interim 18F-fluoride PET/CT study.
Quantitative analyses of 18F-fluoride PET/CT images 
have been conducted to assess its role in predicting out-
comes, by determining the peak SUVmax values of bone 
metastases. Apolo et al.(17) performed 18F-fluoride PET/
CT after 6 and 12 months of standard therapy in prostate 
cancer patients, reporting that progression was associated 
with SUV increases of more than 57%, as well as that a 
greater increase in SUV was associated with worse survival. 
Yu et al.(18) evaluated responses to therapy with dasatinib 
using SUVmax in five target lesions on 
18F-fluoride PET/CT 
and detected only a borderline correlation with PFS; the 
changes also correlated with the ALP level. Another study, 
involving only five patients, showed a reduction in SUVmax 
at 6 and 12 weeks after the use of 223RaCl2
(19). In our popu-
lation, the SUVmax did not correlate with OS. Although the 
above mentioned studies performed 18F-fluoride PET/CT 
for therapeutic evaluation, its precise role in determining 
the early response to therapy has yet to be extensively stud-
ied, especially in terms of assessing survival as an end point.
The reported frequency of the flare phenomenon in 
prostate cancer patients undergoing conventional bone 
scintigraphy ranges from 6% to 25%(20,21). Although the 
flare phenomenon has also been described in patients un-
dergoing 18F-fluoride PET/CT(15), there have been no re-
ports of its frequency in patients treated with 223RaCl2 and 
undergoing 18F-fluoride PET/CT. Although we identified 
the flare phenomenon on 18F-fluoride PET/CT in only a 
small proportion of our patient sample (3%), that propor-
tion is probably higher than in conventional bone scintig-
raphy, given the greater sensitivity of PET/CT. The most 
likely explanation for the fact that the frequency of the 
flare phenomenon was not higher is that our study sample 
was composed of patients with extensive disease, in whom 
the likelihood of progression is greater than is that of a 
response to therapy. In addition, the number of patients 
might have been insufficient to detect this phenomenon.
In our patient sample, the interim 18F-fluoride PET/
CT (%TLF10) after three cycles of 
223RaCl2 was not able to 
predict OS, PFS, TTBE, or BMF. These findings are quite 
similar to those of a previous study, involving ten prostate 
cancer patients treated with 223RaCl2
(22), although the in-
terim 18F-fluoride PET/CT studies were performed at dif-
ferent time points: at baseline; after one (or two) cycles of 
223RaCl2; and at the end of treatment. A correlation with 
outcome was only noted between baseline and end-of-
treatment 18F-fluoride PET/CT results were found to cor-
relate with outcomes, as previously reported(1).
One major limitation of our study was the relatively 
small number of patients. We believe that the interim 18F-
fluoride PET/CT could have potential for the prediction 
of BMF, given that 6 of the 9 patients who evolved to 
BMF showed a reduction in uptake. However, due to the 
small sample size, those results were not significant. An-
other limitation was the fact that it was not possible to ob-
tain histological confirmation in the patients who showed 
progression. Although the 18F-fluoride PET/CT images 
were acquired in different scanners, the same software 
was employed in all quantifications, guaranteeing unifor-
mity in the metrics.
To our knowledge, this is the first study to evaluate 
the role of interim 18F-fluoride PET/CT in predicting the 
response to 223RaCl2 therapy, using quantitative methods 
to determine the skeletal tumor burden. It would be inter-
esting to know whether these findings could be replicated 
in other populations, such as that of breast cancer patients 
treated with 223RaCl2.
CONCLUSION
In prostate cancer patients undergoing 223RaCl2 ther-
apy, interim 18F-fluoride PET/CT performed after three 
cycles of 223RaCl2 does not seem able to predict outcomes. 
It also appears to be unable to differentiate a flare response 
from progressive disease, and we therefore discourage 
the use of interim 18F-fluoride PET/CT to evaluate the 
response to 223RaCl2 therapy in prostate cancer patients. 
There is a need for studies involving a larger number of 
patients and patients with other types of cancer, in order to 
verify our findings.
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